Hamid Emamekhoo
About
Hamid Emamekhoo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery.
According to data from OpenAlex, Hamid Emamekhoo has authored 96 papers receiving a total of 961 indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Pulmonary and Respiratory Medicine, 44 papers in Oncology and 37 papers in Surgery. Recurrent topics in Hamid Emamekhoo's work include Bladder and Urothelial Cancer Treatments (37 papers), Renal cell carcinoma treatment (28 papers) and Cancer Immunotherapy and Biomarkers (26 papers). Hamid Emamekhoo is often cited by papers focused on Bladder and Urothelial Cancer Treatments (37 papers), Renal cell carcinoma treatment (28 papers) and Cancer Immunotherapy and Biomarkers (26 papers). Hamid Emamekhoo collaborates with scholars based in United States, Slovenia and United Kingdom. Hamid Emamekhoo's co-authors include Dieter C. Gruenert, Rosalie Maurisse, David de Semir, Alireza Abdolmohammadi, Christos E. Kyriakopoulos, Tian Zhang, Ana M. Molina, Matthew I. Milowsky, Ralph J. Hauke and Joshua M. Lang and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Cancer.
In The Last Decade
Hamid Emamekhoo
87 papers receiving 947 citations
Hit Papers
Peers
Hamid Emamekhoo
Gurudatta Naik United States
Sophia L. Maund United States
Susanna V. Ulahannan United States
George Philips United States
Zishuo I. Hu United States
Anne Gentil‐Perret France
Germana Tognon Italy
Matin Sheriff United Kingdom
Luiz H. Araujo Brazil
Ramon Andrade de Mello Portugal
Citations per year, relative to Hamid Emamekhoo Hamid Emamekhoo (= 1×)
peers
Gurudatta Naik
Countries citing papers authored by Hamid Emamekhoo
Since
Specialization
Citations
This map shows the geographic impact of Hamid Emamekhoo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hamid Emamekhoo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hamid Emamekhoo more than expected).
Fields of papers citing papers by Hamid Emamekhoo
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Hamid Emamekhoo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hamid Emamekhoo. The network helps show where Hamid Emamekhoo may publish in the future.
Co-authorship network of co-authors of Hamid Emamekhoo
This figure shows the co-authorship network connecting the top 25 collaborators of Hamid Emamekhoo. A scholar is included among the top collaborators of Hamid Emamekhoo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hamid Emamekhoo. Hamid Emamekhoo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Jiang, C.-Y., Omar Alhalabi, Edwin C. Oh, et al.. (2025). 3077P Enfortumab vedotin with pembrolizumab (EVP) treatment outcomes in patients with histologic subtypes of advanced urothelial carcinoma: Analysis of the UNITE study. Annals of Oncology. 36. S1489–S1489.
2.
Lang, Joshua M., Susan F. Slovin, Jamie M. Sperger, et al.. (2024). 1648P Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI). Annals of Oncology. 35. S993–S994.
3.
Yu, Evan Y., Luke T. Nordquist, Salim Yazji, et al.. (2024). A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS5111–TPS5111.
4.
Patel, Manish R., Jessica E. Hawley, S. Srinivas, et al.. (2024). 1597MO Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 35. S962–S963.
5.
Alhalabi, Omar, Dimitra Rafailia Bakaloudi, Amanda Nizam, et al.. (2024). Impact of squamous histology on outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma: Analysis of the UNITE study.. Journal of Clinical Oncology. 42(4_suppl). 651–651.
6.
Jiang, Changying, Omar Alhalabi, Amanda Nizam, et al.. (2024). 8P Factors associated with primary progression in patients with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV): Analysis of the UNITE study. ESMO Open. 9. 102263–102263.
7.
Nizam, Amanda, Li Zhang, Dimitra Rafailia Bakaloudi, et al.. (2024). 1972P Pre-treatment (Tx) risk factors for enfortumab vedotin-induced peripheral neuropathy (EVIPN) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of UNITE. Annals of Oncology. 35. S1142–S1142.
8.
Jang, An‐Soo, Chenyu Jiang, Amanda Nizam, et al.. (2024). 1989P Efficacy of enfortumab vedotin (EV) in patients (pts) with (w) advanced urothelial carcinoma (aUC) who have baseline neuropathy (N) and/or diabetes mellitus (DM): A UNITE study analysis. Annals of Oncology. 35. S1150–S1151.
9.
Cracchiolo, Jennifer R., Ashish Atreja, Hamid Emamekhoo, et al.. (2023). Getting ready for real‐world use of electronic patient‐reported outcomes (ePROs) for patients with cancer: A National Comprehensive Cancer Network ePRO Workgroup paper. Cancer. 129(16). 2441–2449.
10.
McNeel, Douglas G., Hamid Emamekhoo, Jens C. Eickhoff, et al.. (2023). Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer. Journal for ImmunoTherapy of Cancer. 11(12). e008067–e008067.
11.
Taylor, Amy K., Jamie M. Sperger, Marina N. Sharifi, et al.. (2023). Association of emergent neuroendocrine prostate cancer detected by liquid biopsies with survival and treatment resistance.. Journal of Clinical Oncology. 41(6_suppl). 247–247.
12.
Joshi, Monika, Leonard Tuanquin, Junjia Zhu, et al.. (2023). Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023. Journal for ImmunoTherapy of Cancer. 11(2). e006551–e006551.
13.
Park, Yeonhee, Yusuf M. Mohamoud, Hamid Emamekhoo, et al.. (2023). Neutrophil‐to‐eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti‐PD ‐1 therapy. Pigment Cell & Melanoma Research. 36(6). 501–511.
14.
Taylor, Amy K., David Kosoff, Hamid Emamekhoo, Joshua M. Lang, & Christos E. Kyriakopoulos. (2023). PARP inhibitors in metastatic prostate cancer. Frontiers in Oncology. 13. 1159557–1159557.
15.
Lang, Jessica D., Scott T. Tagawa, Susan F. Slovin, et al.. (2022). 1406P Interim results of a phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI). Annals of Oncology. 33. S1188–S1188.
16.
McNeel, Douglas G., et al.. (2022). 1415P Phase II trial of a DNA vaccine with nivolumab in patients with PSA-recurrent, castration-sensitive prostate cancer (nmCSPC). Annals of Oncology. 33. S1192–S1192.
17.
Emamekhoo, Hamid, et al.. (2020). Polycystic Liver Disease in a Patient With Metastatic Renal Cell Carcinoma: A Case Report. Anticancer Research. 40(3). 1527–1534.
18.
Abel, E. Jason, Sara L. Best, Hamid Emamekhoo, et al.. (2018). Percutaneous microwave ablation for local control of metastatic renal cell carcinoma. Abdominal Radiology. 43(9). 2446–2454.
19.
Tzeng, Alice, C. Marcela Díaz‐Montero, Patricia Rayman, et al.. (2018). Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. Targeted Oncology. 13(5). 599–609.
20.
Ye, Lin, Rosalie Maurisse, Jennifer Schwarz, et al.. (2009). Sequence-Specific Correction of Genomic Hypoxanthine-Guanine Phosphoribosyl Transferase Mutations in Lymphoblasts by Small Fragment Homologous Replacement. Oligonucleotides. 20(1). 7–16.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Gurudatta Naik Breakdown of academic impact, for papers by Sophia L. Maund Breakdown of academic impact, for papers by Susanna V. Ulahannan Breakdown of academic impact, for papers by George Philips Breakdown of academic impact, for papers by Zishuo I. Hu Breakdown of academic impact, for papers by Anne Gentil‐Perret Breakdown of academic impact, for papers by Germana Tognon Breakdown of academic impact, for papers by Matin Sheriff Breakdown of academic impact, for papers by Luiz H. Araujo Breakdown of academic impact, for papers by Ramon Andrade de Mello